Report Store

The Report Store is a repository of research reports that are available for online purchase. Each provides an in-depth analysis of a single product or class of products in development within the pharmaceutical, biotechnology, device or diagnostics industries. The goal is to provide actionable insights that enable smart investment decisions around emerging product opportunities. Typically, the reports address:

The scientific and medical rationale for use in the target indication
The strength of available human efficacy and safety data, including the probability of late-phase trial success
Regulatory (eg, FDA) concerns and their likely impact on approval and labeling
Commercial opportunities, including an assessment of the competitive landscape and reimbursement issues.

Sort by

Biogen-Idec's and Knopp Biosciences' dexpramipexole for amyotrophic lateral sclerosis

This report provides an in-depth review of the rationale and phase II dexpramipexole results in ALS as a means to gauge the likelihood of success in phase III.
Learn More

Raptor's RP 103 for nephropathic cystinosis - an orphan genetic disease

A review of RP103's clinical program as a means to gauge regulatory, reimbursement and commercial success. Learn More

Tranzyme’s And Norgine’s Ulimorelin – Clinical, Regulatory And Commercial Prospects

This report explores ulimorelin's novel mechanism, looking at its potential benefit and risk. It also examines the likelihood of phase III success, Entereg as a regulatory precedent, and the market opportunity across the various indications targeted by the sponsors. Learn More

Onyx's Carfilzomib

An in-depth regulatory discussion, as a means to gauge the most likely outcome for carfilzomib on July 27th, the FDA decision date (PDUFA). The report also reviews whether the lower incidence of peripheral neuropathy might be offset by a potential risk of kidney injury, and how this may impact FDA’s decision and its commercial prospects. Learn More

Micromet's blinatumomab: a first-in-class bispecific antibody

A review of the blinatumomab program, the regulatory path to approval and its commercial prospects in acute lymphoblastic leukemia as well as in B-cell NHL, a large opportunity where blinatumomab may face much different challenges. Learn More

GTx's Capesaris - A novel medical castration method

This report explores the risk/benefit profile of Capesaris, as well as the probability of phase III success, the regulatory path to approval, and the market into which it will launch, if successful.
Learn More

Lexicon's LX-4211 - a novel mechanism to treat diabetes

The prospects for LX-4211 and implications of its novel mechanism of action. A review of BMS/AZN’s dapagliflozin program - a bellwether for LX-4211 and the SGLT class.
Learn More

Arqule's tivantinib for NSCLC

This report reviews tivantinib’s pre-clinical and clinical evidence of activity, and the likelihood that it will succeed in late stage development. The report also discusses regulatory considerations, competition and differentiation from other c-MET inhibitors, as well as commercial prospects should tivantinib be approved.

Learn More

Vical's Allovectin - Advancing immunotherapy for metastatic melanoma

This report reviews the evidence for and against Allovectin-7, the odds for success in phase III, potential regulatory risks, and the commercial opportunity in metastatic melanoma for another immunotherapy. Learn More

Cubist's CXA-201 - A novel antibiotic for Gram-negative infections

This report reviews CXA-201’s clinical profile and potential, emerging competition, as well as the market opportunity and commercial prospects for this new antibiotic in the empirical Gram negative treatment setting.
Learn More